Vanguard Group
ALXN

Vanguard Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Vanguard Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-20,367,300
Closed -$3.74B – 4587
2021
Q2 		$3.74B Buy
20,367,300
+798,317
+4% +$137M 0.09% 207
2021
Q1 		$2.99B Buy
19,568,983
+162,215
+0.8% +$25.1M 0.08% 254
2020
Q4 		$3.03B Sell
19,406,768
-437,152
-2% -$56.2M 0.09% 225
2020
Q3 		$2.27B Buy
19,843,920
+2,831,898
+17% +$306M 0.08% 266
2020
Q2 		$1.91B Sell
17,012,022
-166,689
-1% -$17.7M 0.07% 308
2020
Q1 		$1.54B Buy
17,178,711
+414,294
+2% +$40.7M 0.07% 304
2019
Q4 		$1.81B Sell
16,764,417
-84,772
-0.5% -$9.07M 0.06% 346
2019
Q3 		$1.65B Buy
16,849,189
+200,063
+1% +$22.6M 0.06% 352
2019
Q2 		$2.18B Buy
16,649,126
+211,960
+1% +$27.3M 0.08% 262
2019
Q1 		$2.22B Buy
16,437,166
+215,255
+1% +$26.8M 0.09% 234
2018
Q4 		$1.58B Buy
16,221,911
+410,620
+3% +$48.5M 0.07% 300
2018
Q3 		$2.2B Buy
15,811,291
+192,857
+1% +$24.2M 0.09% 231
2018
Q2 		$1.94B Buy
15,618,434
+246,793
+2% +$28.8M 0.08% 250
2018
Q1 		$1.71B Buy
15,371,641
+168,887
+1% +$20.2M 0.07% 288
2017
Q4 		$1.82B Buy
15,202,754
+161,204
+1% +$19.6M 0.08% 268
2017
Q3 		$2.11B Buy
15,041,550
+255,719
+2% +$34.7M 0.1% 206
2017
Q2 		$1.8B Buy
14,785,831
+318,375
+2% +$37.1M 0.09% 245
2017
Q1 		$1.75B Buy
14,467,456
+433,293
+3% +$55.9M 0.09% 234
2016
Q4 		$1.72B Buy
14,034,163
+297,620
+2% +$36.4M 0.1% 221
2016
Q3 		$1.68B Buy
13,736,543
+257,825
+2% +$33.2M 0.1% 212
2016
Q2 		$1.57B Buy
13,478,718
+216,269
+2% +$30.7M 0.1% 221
2016
Q1 		$1.85B Buy
13,262,449
+288,491
+2% +$42.4M 0.12% 164
2015
Q4 		$2.47B Buy
12,973,958
+252,272
+2% +$44.1M 0.17% 115
2015
Q3 		$1.99B Sell
12,721,686
-333,010
-3% -$60.7M 0.14% 133
2015
Q2 		$2.36B Buy
13,054,696
+1,783,179
+16% +$308M 0.16% 120
2015
Q1 		$1.95B Buy
11,271,517
+611,169
+6% +$111M 0.13% 148
2014
Q4 		$1.97B Buy
10,660,348
+382,895
+4% +$70.9M 0.14% 137
2014
Q3 		$1.7B Buy
10,277,453
+191,822
+2% +$31.5M 0.13% 145
2014
Q2 		$1.58B Buy
10,085,631
+189,431
+2% +$29.9M 0.12% 162
2014
Q1 		$1.51B Buy
9,896,200
+391,653
+4% +$62.3M 0.13% 154
2013
Q4 		$1.26B Buy
9,504,547
+190,857
+2% +$22.9M 0.11% 176
2013
Q3 		$1.08B Buy
9,313,690
+184,657
+2% +$20.3M 0.11% 188
2013
Q2 		$842M Buy
+9,129,033
New +$880M 0.09% 233

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Vanguard Group's ALXN Position: Q3 2021 in Review

Vanguard Group sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 20,367,300 shares — an estimated $3.74B sold.

Vanguard Group first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $3.74B in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Vanguard Group reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Vanguard Group sold 20,367,300 Alexion Pharmaceuticals shares in Q3 2021, an estimated $3.74B.
  • Vanguard Group first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Vanguard Group's Alexion Pharmaceuticals position peaked at $3.74B in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Vanguard Group's 13F filing for Q3 2021, filed 12 Nov 2021.